A Phase 1b Study with Selinexor, a First in Class Selective Inhibitor of Nuclear Export (SINE) in Patients with Advanced Sarcomas: An Efficacy Analysis
A Phase 1b Study with Selinexor, a First in Class Selective Inhibitor of Nuclear Export (SINE) in Patients with Advanced Sarcomas: An Efficacy Analysis